Skin care compositions and methods

Abstract

A skin care composition can include a growth factor, such as an epidermal and/or keratinocyte growth factor (EGF, KGF), a DNA repair enzyme encapsulated by a liposome, and a carrier suitable for topical administration of the EGF and/or KGF and DNA repair enzyme to a subject's skin. One, two, or more modalities, such as sonophoresis, can be used to synergistically increase transdermal penetration of compositions. Also disclosed herein is a therapeutic agent for preventing or treating a condition of the gastrointestinal tract.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . A skin care system comprising:
 at least one of an epidermal growth factor (EGF) and a keratinocyte growth factor (KGF) and a first carrier suitable for topical administration;   a DNA repair enzyme encapsulated by a liposome and a second carrier suitable for topical administration; and   a sonophoresis device comprising a generator and a transducer, the device configured to increase transdermal absorption of the EGF and/or KGF and the DNA repair enzyme.   
     
     
         8 . The skin care system of  claim 7 , wherein the sonophoresis device is configured to deliver ultrasonic energy having a frequency of between about 0.7 MHz and about 1.1 MHz. 
     
     
         9 . The skin care system of  claim 7 , wherein the sonophoresis device is configured to deliver ultrasonic energy having an intensity of less than about 3 W/cm 2 . 
     
     
         10 . The skin care system of  claim 7 , wherein the sonophoresis device is configured to deliver continuous ultrasonic energy. 
     
     
         11 . The skin care system of  claim 7 , wherein the sonophoresis device is configured to deliver pulsed ultrasonic energy. 
     
     
         12 . The skin care system of  claim 7 , wherein the sonophoresis device comprises a control configured to deliver ultrasonic energy to the skin for between about 2 minutes and about 15 minutes. 
     
     
         13 . A skin care method, comprising:
 topically administering at least one of a epidermal growth factor (EGF) and a keratinocyte growth factor (KGF) to a subject's skin;   topically administering a DNA repair enzyme encapsulated by a liposome to the subject's skin; and   applying ultrasonic energy through the skin surface to increase absorption of the EGF and/or KGF and the DNA repair enzyme.   
     
     
         14 . The skin care method of  claim 13 , wherein the ultrasonic energy has a frequency of between about 0.7 MHz and about 1.1 MHz. 
     
     
         15 . The skin care method of  claim 13 , wherein the ultrasonic energy is has an intensity of less than about 3 W/cm 2 . 
     
     
         16 . The skin care method of  claim 13 , wherein the ultrasonic energy is delivered continuously. 
     
     
         17 . The skin care method of  claim 13 , wherein the ultrasonic energy is delivered in a pulsed fashion. 
     
     
         18 . The skin care method of  claim 13 , wherein the ultrasonic energy is delivered to the skin surface over a period of between about 2 minutes and about 15 minutes. 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . A method of preventing or treating a condition of the gastrointestinal tract, comprising:
 providing a DNA repair composition, the DNA repair composition comprising at least one DNA repair enzyme, the DNA repair composition configured for administration within the gastrointestinal tract of a patient; and   administering the DNA repair composition to the patient, such that the DNA repair composition is absorbed within the gastrointestinal tract of the patient to treat the condition of the gastrointestinal tract.   
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . (canceled) 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . (canceled) 
     
     
         45 . (canceled) 
     
     
         46 . (canceled)